Maxim Group analyst Naz Rahman upgrades Virpax Pharmaceuticals (NASDAQ:VRPX) from Hold to Buy and announces $3 price target.
Maxim Group Upgrades Virpax Pharmaceuticals to Buy, Announces $3 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.